The IT Future of Medicine: Data-rich, individualised medicine poses unprecedented challenges for IT, in hardware, storage and communication. ITFoM proposes a data-driven, individualised medicine of the future, based on the molecular/physiological/anatomical data from individual patients. ITFoM shall make general models of human pathways, tissues, diseases and ultimately of the human as a whole. Patient individualised versions of the models will then be used to identify personalised prevention/therapy schedules and side effects of drugs. This is the first time that huge IT implications of worldwide individualized patient care will be addressed in combination with genomics and medical requirements. The project outcomes will enable calculation of health, disease, therapy and its effects for individual patients. These may revolutionize our health care with enormous (i) benefits for health (prevention, diagnosis and therapy), (ii) reduction in cost by individualising combinations of a limited number of drugs, and (iii) new commercial opportunities in IT, analytics and health care. This entails nothing less than the transformation of biomedical science from empirical and stochastic to fact based and knowledge driven i.e. based on an ICT paradigm. Prof. Hans Lehrach
The IT Future of Medicine: Data-rich, individualised medicine poses unprecedented challenges for IT, in hardware, storage and communication. ITFoM proposes a data-driven, individualised medicine of the future, based on the molecular/physiological/anatomical data from individual patients. ITFoM shall make general models of human pathways, tissues, diseases and ultimately of the human as a whole. Patient individualised versions of the models will then be used to identify personalised prevention/therapy schedules and side effects of drugs. This is the first time that huge IT implications of worldwide individualized patient care will be addressed in combination with genomics and medical requirements. The project outcomes will enable calculation of health, disease, therapy and its effects for individual patients. These may revolutionize our health care with enormous (i) benefits for health (prevention, diagnosis and therapy), (ii) reduction in cost by individualising combinations of a limited number of drugs, and (iii) new commercial opportunities in IT, analytics and health care. This entails nothing less than the transformation of biomedical science from empirical and stochastic to fact based and knowledge driven i.e. based on an ICT paradigm. Prof. Hans Lehrach